Idorsia's Aprocitentan Shows Strong Efficacy in Obesity and Cardiometabolic Patients

  • Idorsia presented data at AHA Hypertension 2026 showing aprocitentan reduced blood pressure by 15-16 mmHg in obese patients and those across the cardiovascular-kidney-metabolic (CKM) continuum.
  • The drug also demonstrated kidney protective effects, with a 50% reduction in UACR and stable eGFR in CKM patients.
  • PRECISION study post-hoc analyses involved 506 obese patients and 683 CKM patients (stages 2 and 4a).
  • Aprocitentan is approved as TRYVIO in the US and JERAYGO in Europe for resistant hypertension.
  • The findings reinforce the role of endothelin pathway blockade in difficult-to-control hypertension.

Idorsia's findings position aprocitentan as a potential game-changer in treating resistant hypertension, particularly in high-risk populations like obese patients and those with cardiovascular-kidney-metabolic disease. The data supports the growing recognition of the endothelin pathway as a critical target in hypertension management. With 1.4 billion people worldwide living with hypertension and many failing to achieve adequate control, aprocitentan could address a significant unmet medical need.

Therapeutic Differentiation
Whether aprocitentan's endothelin pathway blockade can establish it as a distinct treatment option beyond existing hypertension therapies.
Regulatory Expansion
The pace at which Idorsia can secure additional approvals for aprocitentan in broader patient populations.
Commercial Strategy
How Idorsia will position aprocitentan against competitors in the growing market for resistant hypertension treatments.